OncoMatch/Clinical Trials/NCT07201337
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Is NCT07201337 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for nasopharyngeal cancinoma (npc).
To evaluate the locoregional control, survival rate, toxicity, and quality of life in patients with nasopharyngeal carcinoma treated with reduced prophylactic irradiation doses to the Low-Risk Clinical Target Volume (CTV).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Excluded: Stage DISTANT METASTATIC
non-distant metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Previous chemotherapy treatment
Cannot have received: radiotherapy
Exception: except diagnostic surgery
surgery (except diagnostic) or radiotherapy to the neck or nasopharyngeal regions
Lab requirements
Blood counts
neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥100×10^9/L, and hemoglobin≥ 90 g/L
Kidney function
creatinine ≤ 1.5 upper limit of normal [ULN] or calculated creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula)
Liver function
serum bilirubin ≤ 2.0×ULN, and alanine aminotransferase and aspartate aminotransferase ≤ 2.5×ULN
adequate hematologic function (neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥100×10^9/L, and hemoglobin≥ 90 g/L); adequate renal function (creatinine ≤ 1.5 upper limit of normal [ULN]) or calculated creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula); and adequate hepatic function (serum bilirubin ≤ 2.0×ULN, and alanine aminotransferase and aspartate aminotransferase ≤ 2.5×ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify